협심증 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 약물 분류별, 유통 채널별, 지역별 및 부문별 전망(2026-2033년)

The global angina pectoris drugs market size was valued at USD 12.9 billion in 2025 and is projected to grow from USD 13.4 billion in 2026 to USD 17.6 billion by 2033, at a CAGR of 4.0% from 2026 to 2033. The North America dominated the global market, accounting for the largest revenue share of 40.0% in 2025. Advancements in personalized cardiovascular medicine and novel drug delivery systems are driving market expansion.

Moreover, worldwide market growth is fueled by the escalating prevalence of cardiac disorders, including coronary heart disease. Pharmaceutical companies are investing heavily in clinical trials to develop innovative treatments with improved efficacy, further propelling market growth. These developments are expected to significantly contribute to the market's continued expansion.

The global angina pectoris drugs market is driven by a combination of factors, including the increasing occurrence of cardiovascular diseases worldwide. The growing demand for effective treatments is driven by the fact that cardiovascular diseases are a leading contributor to global mortality rates. Advances in drug delivery systems, such as transdermal patches and sustained-release formulations, are also boosting the efficiency and patient compliance of angina pectoris medications.

The growing geriatric population is another key driver of the market, as the elderly are more susceptible to cardiovascular diseases. This demographic shift presents an opportunity for pharmaceutical companies to develop targeted therapies that address the unique needs of older adults and improve their quality of life. Strategic partnerships and collaborations between pharmaceutical companies and research institutions are also driving market growth by advancing the development of innovative drug formulations and accelerating drug discovery.

Advancements in cardiology treatment, ongoing research and development efforts, and a growing number of drug approvals from regulatory bodies such as the FDA are also driving market growth. The rise in retail pharmacies and patient preference for purchasing angina drugs through these channels is creating market opportunities. As the global population continues to age, there will be increasing demand for effective treatments for angina pectoris, presenting an opportunity for pharmaceutical companies to develop and market new products to meet this growing need.

Global Angina Pectoris Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global angina pectoris drugs market report by type, drug class, distribution channel, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

Stable Angina

Unstable Angina

Microvascular Angina

Prinzmetal Angina

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)

Beta Blockers

Calcium Antagonists

Nitrates

Anticoagulants

Anti-Platelets

Other Drug Classes

• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

• U.S.
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Thailand

Latin America

• Brazil
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Angina Pectoris Drugs Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Angina Pectoris Drugs Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Angina Pectoris Drugs Market: Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Angina Pectoris Drugs Market: Type Movement Analysis, 2026 & 2033 (USD Million)
• 4.3. Stable Angina
  • 4.3.1. Stable Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.4. Unstable Angina
  • 4.4.1. Unstable Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Microvascular Angina
  • 4.5.1. Microvascular Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Prinzmetal Angina
  • 4.6.1. Prinzmetal Angina Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Angina Pectoris Drugs Market: Drug Class Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Angina Pectoris Drugs Market: Drug Class Movement Analysis, 2026 & 2033 (USD Million)
• 5.3. Beta Blockers
  • 5.3.1. Beta Blockers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Calcium Antagonists
  • 5.4.1. Calcium Antagonists Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Nitrates
  • 5.5.1. Nitrates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Anticoagulants
  • 5.6.1. Anticoagulants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Anti-Platelets
  • 5.7.1. Anti-Platelets Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Other Drug Classes
  • 5.8.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Angina Pectoris Drugs Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Angina Pectoris Drugs Market: Distribution Channel Movement Analysis, 2026 & 2033 (USD Million)
• 6.3. Hospital Pharmacy
  • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.4. Retail Pharmacy
  • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Online Pharmacy
  • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Angina Pectoris Drugs Market: Regional Estimates & Trend Analysis

• 7.1. Angina Pectoris Drugs Market Share, By Region, 2026 & 2033 (USD Million)
• 7.2. North America
  • 7.2.1. North America Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Denmark Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Sweden Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Norway Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Japan Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. China Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Australia
    • 7.4.5.1. Australia Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. South Korea
    • 7.4.6.1. South Korea Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Thailand Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. South Africa Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Saudi Arabia Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. UAE Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Kuwait Angina Pectoris Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Pfizer Inc.
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/Strategic Initiatives
  • 8.4.2. Bayer AG
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/Strategic Initiatives
  • 8.4.3. AstraZeneca
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/Strategic Initiatives
  • 8.4.4. Gilead Sciences
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/Strategic Initiatives
  • 8.4.5. Novartis AG
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/Strategic Initiatives
  • 8.4.6. GlaxoSmithKline Plc.
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/Strategic Initiatives
  • 8.4.7. Merck & Co., Inc.
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/Strategic Initiatives
  • 8.4.8. Amgen Inc.
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/Strategic Initiatives
  • 8.4.9. Eli Lilly and Company
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/Strategic Initiatives
  • 8.4.10. Otsuka Pharmaceutical Co., Ltd.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/Strategic Initiatives
  • 8.4.11. Sanofi S.A.
    • 8.4.11.1. Participant's Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Recent Developments/Strategic Initiatives
  • 8.4.12. Boehringer Ingelheim International GmbH
    • 8.4.12.1. Participant's Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Recent Developments/Strategic Initiatives